Connecting you to content on EBSCOhost

Works by Fries, Tea Monk

Results: 4

1

Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.

Published in:

Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2487, doi. 10.1111/dom.14160

By:

Verma, Subodh;
McGuire, Darren K.;
Bain, Stephen C.;
Bhatt, Deepak L.;
Leiter, Lawrence A.;
Mazer, C. David;
Monk Fries, Tea;
Pratley, Richard E.;
Rasmussen, Søren;
Vrazic, Hrvoje;
Zinman, Bernard;
Buse, John B.

Publication type:

Article

2

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.

Published in:

Diabetes, Obesity & Metabolism, 2019, v. 21, n. 7, p. 1745, doi. 10.1111/dom.13698

By:

Verma, Subodh;
Mazer, C. David;
Bain, Stephen C.;
Monk Fries, Tea;
Rasmussen, Søren;
Saevereid, Hans A.;
Nauck, Michael A.;
Pratley, Richard E.;
Zinman, Bernard;
Buse, John B.

Publication type:

Article

3

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.

Published in:

2020

By:

Buse, John B.;
Bain, Stephen C.;
Mann, Johannes F.E.;
Nauck, Michael A.;
Nissen, Steven E.;
Pocock, Stuart;
Poulter, Neil R.;
Pratley, Richard E.;
Linder, Martin;
Monk Fries, Tea;
Ørsted, David D.;
Zinman, Bernard;
LEADER Trial Investigators

Publication type:

journal article

4

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.

Published in:

Obesity (19307381), 2023, v. 31, n. 1, p. 111, doi. 10.1002/oby.23621

By:

Lingvay, Ildiko;
Brown‐Frandsen, Kirstine;
Colhoun, Helen M.;
Deanfield, John;
Emerson, Scott S.;
Esbjerg, Sille;
Hardt‐Lindberg, Søren;
Hovingh, G. Kees;
Kahn, Steven E.;
Kushner, Robert F.;
Lincoff, A. Michael;
Marso, Steven P.;
Fries, Tea Monk;
Plutzky, Jorge;
Ryan, Donna H.

Publication type:

Article